Haloperidol Tablets
DrugHaloperidol tablet 6mg, Oral, Triple/Day
NCT Number: NCT06218524
The study of investigators indicated that TMZ can up-regulate dopamine D2 receptor (DRD2) expression, and mediates Ferroptosis inhibition and chemoresistance of GBM. The clinical data also proved that the DRD2 expression in recurrent GBM is significantly higher than that in primary GBM. Moreover, the DRD2 antagonist haloperidol can attenuate the above function of DRD2, and increase the sensitivity of GBM to the TMZ by inducing fatal autophagy and ferroptosis. In xenograft mice, the combined usage of haloperidol and Temozolomide (TMZ) can significantly inhibit tumor growth and increase overall survival. The investigators' findings have been published in Clinical cancer research. Haloperidol known as a butylbenzene antipsychotic drug, has been widely used in several kinds of mental illnesses, such as depression, schizophrenia, and Bipolar disorder. And the safe dosage of the haloperidol is clear so far. So in this study, the investigators will recruit the patients who suffered from recurrent GBM, and evaluate the effectiveness of single TMZ chemotherapy or combined with haloperidol.
Trial opening soon.
Get Notified18 year–80 year
All sexes
Interventional
Phase 2
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Haloperidol tablet 6mg, Oral, Triple/Day
Temozolomide, 150mg/kg, Oral, Once/Day, 5/28 days
Time frame: 3 months
Detected the percentage of partial relief and complete relief according to RANO criteria.
Time frame: One year
Overall survival was evaluated during follow-up period.
Time frame: One year
If the recurrent GBM underwent surgery resection, the DRD2 expression was detected.
Time frame: One year
Detection the adverse drug reaction of haloperidol
Contact information is provided by the study sponsor or research team.
Southern Medical University, China
Other
Clinical Study for Evaluating the Effectiveness of Haloperidol and Temozolomide Synergism on Adult Recurrence Glioblastoma
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT04373785
Astrocytoma, Glioblastoma
Houston, Texas, United States
View Trial DetailsNCT01777919
Astrocytoma, Glioblastoma
Pátrai, Greece
View Trial DetailsNCT05917821
Astrocytoma, Glioblastoma
View Trial DetailsNCT05958485
Astrocytoma, Glioblastoma
San Francisco, California, United States
View Trial Details